

Development of a Novel Mechanism-Based Therapeutic Targeting Circulating TXNIP for the Treatment of Insulin Resistance

Frinsulin Biotech. Co., Ltd.



METABOLIC	Lead
Product Type	rProtein
Indication	Type 2 Diabetes
Target	TXNIP
MoA(Mechanism of Action)	Inhibits insulin resistance through TXNIP inhibition
Competitiveness	First-in-class therapeutic approach targeting a novel mechanism associated with insulin resistance
Development Stage	Lead
Route of Administration	Subcutaneous injection

Any unauthorized distribution or reproduction of this material is strictly prohibited.